Pembrolizumab trials for Early Stage Triple-Negative Breast Carcinoma

All Pembrolizumab trials · All Early Stage Triple-Negative Breast Carcinoma trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Early Stage Triple-Negative Breast Carcinoma

• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
  NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
  NCT07407920 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 963 locations

Common questions

How many trials study Pembrolizumab for Early Stage Triple-Negative Breast Carcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.